Artificial intelligence-assisted diagnosis of hematologic diseases based on bone marrow smears using deep neural networks

CoTCoNet: An optimized coupled transformer-convolutional network with an adaptive graph reconstruction for leukemia detection

BACKGROUND

Swift and accurate blood smear analyses are crucial for diagnosing leukemia and other hematological malignancies. However, manual leukocyte count and morphological evaluation remain time-consuming and prone to errors. Additionally, conventional image processing methods struggle to differentiate cells due to visual similarities between malignant and benign cell morphology.

METHOD

In response to above challenges, we propose Coupled Transformer Convolutional Network (CoTCoNet) framework for leukemia classification. CoTCoNet integrates dual-feature extraction to capture long-range global features and fine-grained spatial patterns, facilitating the identification of complex hematological characteristics. Additionally, the framework employs a graph-based module to uncover hidden, biologically relevant features of leukocyte cells, along with a Population-based Meta-Heuristic Algorithm for feature selection and optimization. Furthermore, we introduce a novel combination of leukocyte segmentation and synthesis, which isolates relevant regions while augmenting the training dataset with realistic leukocyte samples. This strategy isolates relevant regions while augmenting the training data with realistic leukocyte samples, enhancing feature extraction, and addressing data scarcity without compromising data integrity.

RESULTS

We evaluated CoTCoNet on a dataset of 16,982 annotated cells, achieving an accuracy of 0.9894 and an F1-Score of 0.9893. We tested CoTCoNet on four diverse, publicly available datasets (including those above) to assess generalizability. Results demonstrate a significant performance improvement over existing state-of-the-art approaches.

CONCLUSIONS

CoTCoNet represents a significant advancement in leukemia classification, offering enhanced accuracy and efficiency compared to traditional methods. By incorporating explainable visualizations that closely align with cell annotations, the framework provides deeper insights into its decision-making process, further solidifying its potential in clinical settings.

A Chronological Overview of Using Deep Learning for Leukemia Detection: A Scoping Review

Leukemia is a rare but fatal cancer of the blood. This cancer arises from abnormal bone marrow cells and requires prompt diagnosis for effective treatment and positive patient prognosis. Traditional diagnostic methods (e.g., microscopy, flow cytometry, and biopsy) pose challenges in both accuracy and time, demanding an inquisition on the development and use of deep learning (DL) models, such as convolutional neural networks (CNN), which could allow for a faster and more exact diagnosis. Using specific, objective criteria, DL might hold promise as a tool for physicians to diagnose leukemia. The purpose of this review was to report the relevant available published literature on using DL to diagnose leukemia. Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, articles published between 2010 and 2023 were searched using Embase, Ovid MEDLINE, and Web of Science, searching the terms "leukemia" AND "deep learning" or "artificial neural network" OR "neural network" AND "diagnosis" OR "detection." After screening retrieved articles using pre-determined eligibility criteria, 20 articles were included in the final review and reported chronologically due to the nascent nature of the phenomenon. The initial studies laid the groundwork for subsequent innovations, illustrating the transition from specialized methods to more generalized approaches capitalizing on DL technologies for leukemia detection. This summary of recent DL models revealed a paradigm shift toward integrated architectures, resulting in notable enhancements in accuracy and efficiency. The continuous refinement of models and techniques, coupled with an emphasis on simplicity and efficiency, positions DL as a promising tool for leukemia detection. With the help of these neural networks, leukemia detection could be hastened, allowing for an improved long-term outlook and prognosis. Further research is warranted using real-life scenarios to confirm the suggested transformative effects DL models could have on leukemia diagnosis.

Digital Microscopy Augmented by Artificial Intelligence to Interpret Bone Marrow Samples for Hematological Diseases

Analysis of bone marrow aspirates (BMAs) is an essential step in the diagnosis of hematological disorders. This analysis is usually performed based on a visual examination of samples under a conventional optical microscope, which involves a labor-intensive process, limited by clinical experience and subject to high observer variability. In this work, we present a comprehensive digital microscopy system that enables BMA analysis for cell type counting and differentiation in an efficient and objective manner. This system not only provides an accessible and simple method to digitize, store, and analyze BMA samples remotely but is also supported by an Artificial Intelligence (AI) pipeline that accelerates the differential cell counting process and reduces interobserver variability. It has been designed to integrate AI algorithms with the daily clinical routine and can be used in any regular hospital workflow.

Evaluation of deep learning training strategies for the classification of bone marrow cell images

BACKGROUND AND OBJECTIVE

The classification of bone marrow (BM) cells by light microscopy is an important cornerstone of hematological diagnosis, performed thousands of times a day by highly trained specialists in laboratories worldwide. As the manual evaluation of blood or BM smears is very time-consuming and prone to inter-observer variation, new reliable automated systems are needed.

METHODS

We aim to improve the automatic classification performance of hematological cell types. Therefore, we evaluate four state-of-the-art Convolutional Neural Network (CNN) architectures on a dataset of 171,374 microscopic cytological single-cell images obtained from BM smears from 945 patients diagnosed with a variety of hematological diseases. We further evaluate the effect of an in-domain vs. out-of-domain pre-training, and assess whether class activation maps provide human-interpretable explanations for the models' predictions.

RESULTS

The best performing pre-trained model (Regnet_y_32gf) yields a mean precision, recall, and F1 scores of 0.787±0.060, 0.755±0.061, and 0.762±0.050, respectively. This is a 53.5% improvement in precision and 7.3% improvement in recall over previous results with CNNs (ResNeXt-50) that were trained from scratch. The out-of-domain pre-training apparently yields general feature extractors/filters that apply very well to the BM cell classification use case. The class activation maps on cell types with characteristic morphological features were found to be consistent with the explanations of a human domain expert. For example, the Auer rods in the cytoplasm were the predictive cellular feature for correctly classified images of faggot cells.

CONCLUSIONS

Our study provides data that can help hematology laboratories to choose the optimal training strategy for blood cell classification deep learning models to improve computer-assisted blood and bone marrow cell identification. It also highlights the need for more specific training data, i.e. images of difficult-to-classify classes, including cells labeled with disease information.

Early warning and diagnosis of liver cancer based on dynamic network biomarker and deep learning

Background

Early detection of complex diseases like hepatocellular carcinoma remains challenging due to their network-driven pathology. Dynamic network biomarkers (DNB) based on monitoring changes in molecular correlations may enable earlier predictions. However, DNB analysis often overlooks disease heterogeneity.

Methods

We integrated DNB analysis with graph convolutional neural networks (GCN) to identify critical transitions during hepatocellular carcinoma development in a mouse model. A DNB-GCN model was constructed using transcriptomic data and gene expression levels as node features.

Results

DNB analysis identified a critical transition point at 7 weeks of age despite histological examinations being unable to detect cancerous changes at that time point. The DNB-GCN model achieved 100% accuracy in classifying healthy and cancerous mice, and was able to accurately predict the health status of newly introduced mice.

Conclusion

The integration of DNB analysis and GCN demonstrates potential for the early detection of complex diseases by capturing network structures and molecular features that conventional biomarker discovery methods overlook. The approach warrants further development and validation.

Artificial Intelligence-Assisted Diagnostic Cytology and Genomic Testing for Hematologic Disorders

Artificial intelligence (AI) is a rapidly evolving field of computer science that involves the development of computational programs that can mimic human intelligence. In particular, machine learning and deep learning models have enabled the identification and grouping of patterns within data, leading to the development of AI systems that have been applied in various areas of hematology, including digital pathology, alpha thalassemia patient screening, cytogenetics, immunophenotyping, and sequencing. These AI-assisted methods have shown promise in improving diagnostic accuracy and efficiency, identifying novel biomarkers, and predicting treatment outcomes. However, limitations such as limited databases, lack of validation and standardization, systematic errors, and bias prevent AI from completely replacing manual diagnosis in hematology. In addition, the processing of large amounts of patient data and personal information by AI poses potential data privacy issues, necessitating the development of regulations to evaluate AI systems and address ethical concerns in clinical AI systems. Nonetheless, with continued research and development, AI has the potential to revolutionize the field of hematology and improve patient outcomes. To fully realize this potential, however, the challenges facing AI in hematology must be addressed and overcome.